medigraphic.com
ISSN 0210-5187 (Electronic)

2015, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2015; 43 (3)

Paraneoplastic process or side effect to cetuximab?

Alcántara LS, Peral RF, Camacho MFM

Language: Spanish
References: 10
Page: 229-232
PDF size: 485.18 Kb.


ABSTRACT

Acquired ichthyosis is a rare cutaneous disorder characterized by dry, rough skin with prominent scaling that involves symmetrically the trunk and limbs, especially on the extensor surfaces. It appears most commonly in adults in association with malignant, autoimmune, metabolic, endocrine, and infectious diseases. We describe an adult with acquired ichthyosis in whom a tumor recurrence was detected.


REFERENCES

  1. Hueso L, Requena C, Alfaro-Rubio A, Serra-Guillén C. Ictiosis paraneoplásica. Actas Dermosifiliogr. 2008; 99: 317-318.

  2. Abreu VAM, Howard MS. Diagnosis and treatment of cutaneous paraneoplastic disorders. Dermatol Ther. 2010; 23: 662-675.

  3. Fleckman P, DiGiovanna JJ. Ictiosis. En: Gilchrest BA, Katz SE, Goldsmith LA, Wolff K, Katz SI, Paller AS y cols. Trastornos de la diferenciación y la queratinización epidérmicas. En: Fitzpatrick. Dermatología en Medicina General. 7.a ed. Buenos Aires: Médica Panamericana; 2009. pp. 421-22.

  4. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011; 29: 541-547.

  5. Okulicz JF, Schwartz RA. Hereditary and acquired ichthyosis vulgaris. Int J Dermatol. 2003; 42: 95-98.

  6. Guhl G, González-de Arriba A, Daudén E. Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico. Actas Dermatosifiliogr. 2006; 97: 296-310.

  7. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009; 161: 515-521.

  8. González VM, Díaz A, Santos A, Bas CA, Cóppola F, Casas G et al. Manifestaciones cutáneas de nuevas drogas oncológicas: inhibidores del receptor del factor de crecimiento epidérmico y prodrogas del 5- fluoracilo. Dermatol Argent. 2008; 14: 281-287.

  9. Rodríguez-Murphy E, Villanueva-Herraiz S, Ortega-García MP, Pérez-Feliu A, López-Montenegro S, Camps-Herrero C. Toxicidad cutánea asociada a cetuximab en cáncer colorrectal metastásico. Farm Hosp. 2011; 35: 114-120.

  10. Stinzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013; 132: 236-245.




2020     |     www.medigraphic.com